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ABSTRACT
Recent exponential growth in the throughput
of next-generation DNA sequencing platforms has
dramatically spurred the use of accessible and
scalable targeted resequencing approaches.
This includes candidate region diagnostic
resequencing and novel variant validation from
whole genome or exome sequencing analysis.
We have previously demonstrated that selective
genomic circularization is a robust in-solution
approach for capturing and resequencing thou-
sands of target human genome loci such as exons
and regulatory sequences. To facilitate the design
and production of customized capture assays
for any given region in the human genome, we
developed the Human OligoGenome Resource
(http://oligogenome.stanford.edu/). This online
database contains over 21 million capture oligo-
nucleotide sequences. It enables one to create
customized and highly multiplexed resequencing
assays of target regions across the human
genome and is not restricted to coding regions. In
total, this resource provides 92.1% in silico
coverage of the human genome. The online server
allows researchers to download a complete reposi-
tory of oligonucleotide probes and design
customized capture assays to target multiple
regions throughout the human genome. The
website has query tools for selecting and evaluating
capture oligonucleotides from specified genomic
regions.
INTRODUCTION
Using next-generation DNA sequencing (NGS)
technologies, there has been a dramatic increase in
intermediate-scale, targeted resequencing applications.
This is a generally useful approach for discovering poly-
morphisms and mutations of interest among candidate
regions and validating novel variants and mutations
from complete genomes and exomes (1,2). NGS-based
targeted resequencing also has immediate application as
a clinical diagnostic for identifying pathogenic mutations
in medical conditions such as inherited diseases and
cancer. Therefore, it has become increasingly important
to develop accessible, cost effective and ﬂexible methods
that can be used to design customized capture assays tar-
geting any region throughout the entire human genome
beyond coding sequences. Currently there is very little
available with regard to conducting targeted resequencing
of non-coding human genome regions. We present a
genome-wide solution towards targeted resequencing of
loci from the human genome. Relying on a capture tech-
nology we developed, our genome-wide design covers the
human genome with in-solution capture probes. As a
result, it provides both exome coverage as well as
facilitating the analysis of non-coding regions such as pro-
moters and regulatory sequences. These non-coding
regions are of increasing interest with regard to
disease-related polymorphisms and mutations.
As recently described by Natsoulis et al. (3), this
in-solution capture approach enables targeted
resequencing of large sets of genomic loci targets up to
1Mb and potentially higher. Using highly multiplexed
pools of single-stranded 80-mer capture oligonucleotides
to circularize target genomic regions en masse (Figure 1),
this capture assay enables the ampliﬁcation of
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common to all targets. A capture oligonucleotide contains
two single-stranded capture arm sequences that mediate
circularization by hybridizing speciﬁcally to the comple-
mentary ﬂanking sequences of a genomic target. A ﬁxed
sequence general motif links the capture arm oligonucleo-
tides to form a complete capture oligonucleotide with
80bp length. Each circularization reaction also incorpor-
ates a 40-bp universal vector oligonucleotide that comple-
ments the capture oligonucleotide’s general motif. This
vector provides the universal primer sequences necessary
for downstream ampliﬁcation. Previously, we designed a
set of capture oligonucleotides spanning the human exome
(http://oligoexome.stanford.edu) and demonstrated that
customized capture assays could be easily developed
using this resource (3).
In brief, the full protocol includes the following key
steps (Figure 1): (i) genomic DNA is subject to restriction
enzyme digestion by a single enzyme; (ii) the addition of
capture oligonucleotides pools that are speciﬁc to a given
restriction enzyme and the vector sequence circularizes
genomic targets; (iii) 50 exonuclease cleaves unbound 50
sequence (the 50 ﬂap); (iv) circularization is completed by
ligation; and (v) a uracil glycosylase reaction linearizes
circularized molecules to produce capture regions
ﬂanked by universal primer sequences. These molecules
can then be uniformly ampliﬁed by PCR and prepared
for sequencing.
As has been described, this assay successfully targets up
to 1Mb of human sequence and can accommodate the
highly multiplexed capture of thousands of loci (3).
Additionally, the technology achieves both high-
sensitivity and high-speciﬁcity human genomic capture
across target regions up to 800bp in length. On-target
regions of >10-fold coverage make up >85% of the
original targets. Off-target capture as we recently
demonstrated was <5%. Based on a published cost assess-
ment (3), the overall assay is signiﬁcantly less costly than
common capture methods such as multiplex PCR and
in-solution capture. The procedure uses <100ng of
DNA per individual sample, which makes it ideal for
clinical applications with limited sample material, and
the capture assay can be completed in several days.
Finally, this capture assay can be adapted for multiple
sequencing platforms. The most recent application as
described by Natsoulis et al. (3) uses next-generation
Illumina technology for downstream sequencing, but it
may be adapted for use with other next-generation se-
quencers, as we have previously demonstrated with
Roche’s 454 sequencer (4).
This selective capture protocol introduces several mo-
lecular constraints that must be considered in identifying
Figure 1. Schema for target-speciﬁc capture and ampliﬁcation by selective genomic circularization. This schema for the Natsoulis et al. (3) capture
protocol describes the major steps for conducting capture and ampliﬁcation of a target region. The light blue squiggles at the top of the ﬁgure
indicate restriction enzyme recognition sites that are cut by the addition of a single restriction enzyme. ROI stands for region of interest (i.e. target
region), green bars indicate capture arms, green circles indicate capture arm hybridization sites and red bars indicate universal primer sequence.
The protocol described by this ﬁgure is performed separately for each restriction enzyme.
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ligation in Step 4, the termini of a captured DNA
sequence must lie ﬂush to the 40-bp vector oligonucleo-
tide. The 30 capture arm of a successful capture oligo-
nucleotide must therefore hybridize precisely at the 30
terminus of a restriction fragment containing the
genomic region of interest. The 50 exonuclease in Step 3
enables ﬂexible placement of the 50 capture arm by
removing the 50 ﬂap produced by genomic DNA that
extends beyond the capture arm. These molecular mech-
anisms complicate capture arm design and render the pro-
cedure intractable by standard primer design software.
Designing capture arms that cover any given human
genome target represents a major challenge to
disseminating this technology to interested users.
To facilitate designing customized targeted
resequencing assays for any human genome region, we
have created the Stanford Human OligoGenome
Resource, a database of oligonucleotide capture sequences
that span the human genome. Using our previous experi-
ence in designing and implementing assays, we improved
the design method to avoid issues which decrease capture
efﬁciency (3). This unique resource has extensive utility
given that it provides coverage for capture targets
beyond the 3% of the coding region portion (e.g.
exome) of the human genome. The OligoGenome
website (http://oligogenome.stanford.edu/) provides an
interface for browsing, ﬁltering and downloading
capture oligonucleotide sequences based upon user
queried genomic regions and annotation-based con-
straints. The capture oligonucleotide designs and the
search tools expedite the experimental design of
customized captures assays and provides researchers
with the ability to query both inside and outside of the
coding regions of the human genome. Given its low cost
and limited infrastructure requirements (3), this resource
greatly improves the accessibility of highly multiplexed
genomic target capture and resequencing for researchers.
MATERIALS AND METHODS
Capture oligonucleotide sequence generation
We created the Capture Oligonucleotide Annotation and
Creation in Human (COACH) ruby suite to generate
capture oligonucleotides for the human genome in silico.
The suite has two primary modules: a Capture
Oligonucleotide Generator (COG) that ﬁnds putative
capture arm sites and a Refactoring Engine for INvalid
Selection (REINS) that removes sites which fail to pass all
speciﬁed constrains. As input, the program takes a 2-bit
genome ﬁle, a set of restriction enzymes and one or more
bed-formatted annotation ﬁles. The suite processes the re-
striction enzymes independently and outputs a set of
capture oligonucleotides that maximizes genome
coverage for each enzyme.
To generate the capture probes for the Stanford Human
OligoGenome Resource, we used the UCSC hg19 genome
build for chromosomes 1–22; X and Y (5). The coordin-
ates for these regions exactly match the coordinates of
NCBI genome Build 37. We chose the four restriction
enzymes MseI, BfaI, Sau3AI and CViQI to deﬁne our
in silico-cut sites based upon empirical results from
Natsoulis et al. (3). Finally, we used UCSC dbSNP131
annotations to deﬁne common variants (6) and a 24-mer
mapability track from ENCODE to provide an
application-speciﬁc repeat mask (7,8). For a given
24-mer in the human genome, the mapability track indi-
cates how many other 24-mers in the genome have a
sequence that differs by two or fewer bases.
Determination of exon coverage relied on the Consensus
Coding Sequence (CCDS) Project (9) for hg19.
COG uses a greedy algorithm that guarantees selection
of capture arms that maximize genomic coverage given the
constraints in REINS. COG signiﬁcantly improves upon
the TargetedOligoDesign program described in Natsoulis
et al. (3), which evaluated a ﬁxed set of oligonucleotide
capture arms for each target region. For each chromo-
some, COG deﬁnes a set of genomic target regions such
that each region is bounded by adjacent restriction sites.
Within each target region, COG ﬁnds the pair of plus
strand capture arms that would achieve greatest
coverage of the region and submits them to REINS for
validation. It continues to generate capture arm sites in
decreasing order of coverage until REINS either validates
a pair of sites or until no further sites are available. The
same procedure is repeated for minus strand capture arms.
It also tests for a combination of minimally overlapping
plus and minus strand capture arms. COG compares the
three capture sequence sets returned by this process and
outputs the set that achieves the greatest coverage of the
queried region. In the case of a tie for coverage, it selects
the set that covers the fewest bases redundantly. If no
valid set of capture arms is available, COG does not
produce any output for that target region.
In order to ensure highly sensitive and speciﬁc capture,
REINS applied the following, stringent constraints to the
capture oligonucleotide sequences generated for the
Stanford Human OligoGenome Resource. These rules
correspond to the empirical best practices empirically
determined by Natsoulis et al. (3):
(i) Capture arms are 20bp in length;
(ii) The sequences in a pair of capture arms must have
the same polarity with respect to the reference
genome;
(iii) 30 capture arms must be ﬂush to a restriction site;
and
(iv) The maximum size of a DNA molecule targeted
by a capture oligonucleotide is 800bp and the
minimum size is 100bp.
Also, REINS applies rules based on genome-speciﬁc
annotations to improve capture performance in human
genomic target sequences. REINS rejects capture arm se-
quences that would hybridize to regions containing known
variants from dbSNP131. Additionally, because certain
common variants disrupt restriction sites of interest or
introduce new restriction sites, it ensures that capture
arms mediate circularization both in the presence and in
the absence of these variable cut sites. REINS uses the
24-mer mapability track described above to detect
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to inefﬁcient reactions or non-speciﬁc, off-target capture.
To prioritize highly speciﬁc capture arms, we ran COACH
three times, using different mapability constraints based
on the 24-mer mapability track to create three tiers of
oligos: (i) Tier 1: oligos must fall within uniquely
mapable regions; (ii) Tier 2: oligos must fall within
regions mapping to fewer than 10 other regions; and (iii)
Tier 3: no mapability restriction. We used capture arms
from Run 2 to ﬁll in gaps in coverage left after Run 1, and
similarly ﬁlled remaining gaps with oligos from Run 3.
The combination of these genome-speciﬁc rules and par-
ameters constitutes a stringent constraint engine that
enforces capture oligonucleotide quality.
Quality control annotation for capture oligonucleotides
We generated annotations for each capture oligonucleo-
tide produced by COACH to serve as a proxy for capture
efﬁciency and capture speciﬁcity. Among them are param-
eters which we previously had demonstrated are important
for mediating on-target and efﬁcient capture. The follow-
ing annotations apply to each capture arm for any given
oligonucleotide, and all repeat annotations are speciﬁc to
the human genome: (i) number of exact sequence matches
present in the human genome; (ii) number of matches dif-
fering by one base, (iii) number of matches differing by
two bases; and (iv) GC content. Parameters 1–3 inﬂuence
the on-target capture efﬁciency. As was previously
demonstrated, one can reduce off-target capture by
avoiding repetitive regions of the genome in either one
or both of the capture arm sequences. We used bowtie
(10) to determine in silico the number of off-target
regions per oligonucleotide capture arm sequences. We
considered an off-target capture to occur if the capture
arms aligned between 100 and 1000bp from each other
with zero mismatches and had the correct relative orien-
tation. We deﬁned these positions as paralogs (P) of the
intended capture site.
Database construction
The Stanford Human OligoGenome Resource (http://
oligogenome.stanford.edu) runs on a 2 2.27GHz Quad
Core Intel Xeon E5520 server, with 24GB memory and
Ubuntu 9.10 operating system. The web application is im-
plemented in Ruby on Rails 2.3.8, running under
Passenger 2.2.15. The underlying database is MySQL
5.0.42 community edition, which is hosted on a separate
database server. Query and data download is via any
current web browser. Recommended browsers and
versions are: Internet Explorer 7.0+; Firefox 3.0+; Safari
5.0+; or Chrome (any version).
RESULTS
Coverage of the human genome
The Stanford Human OligoGenome Resources achieves
92.1% in silico coverage of the entire human genome
using the four restriction enzymes MseI, BfaI, Sau3AI
and CViQI. In total,  21.8 million probes capture 2.85
billion nucleotide positions at least once. Of these
probes, 20.2 million that cover 88.4% of the genome are
predicted to have a unique capture site due to the absence
of paralogous regions (Table 1). Nearly 720000 probes
cover the CCDS-coding regions (99.65% coverage) for
the 22 April 2011 release of CCDS (Table 2).
Approximately 70000 of these capture oligonucleotides
have only one predicted target site, providing 97.12%
coverage of the CCDS-annotated coding regions at high
speciﬁcity. At least 77.2% of the genome is covered by
capture oligonucleotides from two or more different re-
striction enzymes (91.5% of CCDS regions), which
allows for experimental redundancy. As  50% of the
human genome is highly repetitive, these total coverage
numbers indicate that the capture design successfully
bridges short repetitive sequences such as Alu elements
by placing capture arms in uniquely mapping region on
Table 1. Summary statistics for all capture oligonucleotides designed to target human genome Build 37/hg19
Statistics for whole genome capture BfaI CviQI MseI Sau3AI Total
Tier 1 only
Total number of oligos 4049706 2999049 4825988 3246400 15121143
Average capture length (bases) 401 483 269 430 381
Total bases covered (megabases) 1614 1441 1295 1388 2311
Percent of genome covered 52.14 46.54 41.83 44.83 74.64
Percent of oligos with U0>1 4.71 5.13 5.08 5.06 4.99
Percent of oligos with paralogs>0 0.07 0.07 0.06 0.07 0.07
Percent of genome covered with paralogs removed 52.10 46.50 41.80 44.80 74.60
Tiers 1, 2 and 3 combined
Total number of oligos 5787809 4362946 6757372 4938767 21846894
Average capture length (bases) 410 496 280 426 391
Total bases covered (megabases) 2160 1978 1760 1938 2852
Percent of genome covered 69.79 63.89 56.85 62.61 92.14
Percent of oligos with U0>1 23.99 24.60 23.23 28.60 24.92
Percent of oligos with paralogs>0 6.96 6.48 7.25 8.90 7.39
Percent of genome covered with paralogs removed 64.91 59.41 52.32 57.67 88.43
Tier 1 oligonucleotides are the subset of targeting molecules generated with the strictest repeat masking parameters based upon k-mer mapability.
Tiers 1, 2 and 3 represent all oligonucleotides in the database. This table illustrates that the looser mapability masking parameters used in Tiers 2 and
3 allowed for increased coverage but with a higher probability of having off-target binding and ampliﬁcation.
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given genomic target region are also listed in Table 1.
Capture oligonucleotide human genome mapping
As described in the ‘Materials and Methods’ section, we
established three tiers of mapability to assess off-target
capture. Tier 1 oligonucleotides are the subset of targeting
molecules generated with the strictest repeat masking par-
ameters based upon k-mer mapability (Table 1). Tiers 2
and 3 have fewer constraints on their presence in the
genome and are more susceptible to off-target capture.
Combined Tiers 1, 2 and 3 represent all oligonucleotides
in the database. Figure 2 additionally illustrates the ad-
vantage of the multitiered approach to repeat masking the
oligonucleotide capture sites. Tier 1 provides highly
speciﬁc capture oligonucleotides with reduced coverage,
while the addition of subsequent tiers with reduced
repeat masking achieve higher coverage at the cost of
less efﬁcient reactions through off-target capture.
Interface for the Human OligoGenome
The Human OligoGenome Resource website presents an
intuitive interface for selecting and downloading capture
oligonucleotides for customized assays to mediate targeted
resequencing. Users can download all probe sets by select-
ing gzipped ﬂat ﬁles organized by the chromosome (Figure
3a). Users can also select all capture oligonucleotides from
speciﬁed genomic regions using the Query Capture Seqs
tool, which either takes chromosome, start position and
end position as input or allows the user to upload a bed
ﬁle of capture regions as input (Figure 3b). Before
submitting the query, the user may also choose to ﬁlter
results by the repeat annotations discussed below and by
tier number. Each row of output from this tool presents
information for a single capture oligonucleotide. The ﬁrst
set of ﬁelds contains information about the oligonucleo-
tide sequence and genomic target, including chromosome
(Chromosome), 1-based capture region start position
(Capture Start), and 1-base capture region end
position (Capture End). The Length column calculates
total capture region length, and the Polarity column
identiﬁes the strand with which the capture arms hybrid-
ize relative to the reference sequence. The 5prime
Capture Arm and the 3prime Capture Arm columns
contain the 20bp sequences for the 50 capture arm and
the 30 capture arm, respectively (Figure 3c). The web-
site also generates a table describing the in silico
Figure 2. In silico coverage by the set of capture oligonucleotides from the Human OligoGenome Resource. Coverage is across (a) the whole genome
and (b) the regions deﬁned by CCDS in each successive tier of 24-mer repeat masking. Tier 1 oligonucleotides are the subset of targeting molecules
generated with the strictest repeat masking parameters based upon k-mer mapability. Tiers 1, 2 and 3 represent all oligonucleotides in the database.
The restriction enzyme count on the x-axis is the number of restriction enzymes for which the OligoGenome database contains an oligonucleotide
that can capture a given base. Zero depth indicates the set of positions for which no capture oligonucleotides exist. As expected, fewer repeat mask
restrictions lead to a greater number of positions covered by multiple restriction enyzmes’ oligonucleotides.
Table 2. Summary statistics describing the in silico percent capture of CCDS regions by the combined set of oligonucleotide probes
Statistics for CCDS capture for all tiers BfaI CviQI MseI Sau3AI Total
Total number of oligos covering CCDS target area 182483 178338 158445 200019 719285
Average capture length (bases) 521 550 419 489 497
Total bases covered (megabases) 25.286 23.270 22.162 24.04 31.70
Percent of CCDS covered 79.49 73.15 69.67 75.58 99.65
Percent of oligos with paralogs>0 2.89 2.85 3.00 3.03 2.94
Percent of CCDS covered with paralogs removed 76.96 70.85 67.36 73.02 97.12
Exonic regions prove possible to capture with high sensitivity and speciﬁcity due to their high k-mer complexity.
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queried regions, both per region and in total across all
regions.
The output also includes the annotations generated by
COACH. These include GC content, the number of exact
sequence matches present in the human genome (U0), the
number of matches differing by one base (U1), the number
of matches differing by two bases (U2) and the number
of in silico off target capture regions (Paralogs).
Additionally, each Oligo Name ﬁeld provides a hyperlink
to a page that displays restriction enzyme identity
(Enzyme) and full capture oligonucleotide sequence
(Capture Oligo) for the speciﬁed oligo (Figure 3d). The
user can download the oligonucleotide entries returned
by the Query Capture Seqs tool by clicking on the
Export Oligos button at the top of the page, which
produces a tab-delimited text ﬁle containing all 10 ﬁelds
described above, as well as the genome build and
download date. The user may also choose to export the
data to UCSC as a custom track (11). All data on the
Human OligoGenome Resource website are freely
accessible.
Figure 3. A brief overview of the OligoGenome website and its query tools. You may (a) download all capture oligonucleotides directly or (b) search
for capture oligos that target a speciﬁc interval entered on the page or a set of intervals uploaded in bed format. (c) After the submission of queried
regions, you may view the returned capture oligonucleotides on the website, download the table in bed format, or export the results to the UCSC
Genome Browser to view as a track. (d) Additionally, clicking an oligo name will bring you to a page with additional information, including the full
80-bp capture oligonucleotide.
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of-interest and then downloads the overlapping capture
oligonucleotide sequences. We recommend using Tier 1
capture oligonucleotides and then individually selecting
lower tier oligonucleotides to ﬁll speciﬁc gaps when
needed. Also, choosing oligonucleotides with a GC
content <75% will improve general capture efﬁciency.
After oligonucleotides are synthesized, they should be
pooled in equimolar ratio to each other based on their
afﬁliated restriction enzyme.
DISCUSSION
To facilitate targeted resequencing of the human genome,
we have developed and released the Human OligoGenome
Resource. It covers >92% of the human genome with
capture oligonucleotides that can be used in robust
in-solution capture assays using the selective genomic cir-
cularization method (3). This high level of in silico
coverage is partly attributable to our designs capability
to straddle over repetitive sequences in the human
genome. In particular, the Human OligoGenome
Resource provides for the ﬁrst time a general resource to
capture and target resequence non-coding regions such as
promoters and regulatory sequences which are of
increasing interest in regards to disease-related poly-
morphisms and mutations. It uses a simple web interface
to provide access to capture oligonucleotide sequences for
the entire human genome. These sequences facilitate rapid
experiment design for using the capture technology as
described in Natsoulis et al. (3). The capture oligonucleo-
tides can be ordered and synthesized from any commercial
vendor or core oligonucleotide synthesis facility,
combined to form highly multiplexed reagent pools and
downstream sequencing can be conducted using any NGS
platform. These probes also serve as a useful resource for
other selective circularization technologies. The recently
published paper by Johansson et al. (12) presents a com-
parable capture method for which the OligoGenome
capture oligonucleotides can be easily adapted. The
Human OligoGenome Resource site will facilitate previ-
ously untenable studies in genetic and clinical
resequencing and expedite variant discovery and
validation.
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